by Mike Presbyla | Aug 6, 2018 | News
First two patients enrolled in Phase 1/2 clinical study of KB103, a first-in-class topical gene therapy for the treatment of dystrophic epidermolysis bullosa. PITTSBURGH, Aug. 06, 2018 (GLOBE NEWSWIRE) — Krystal Biotech (NASDAQ:KRYS), a gene therapy company...
by Mike Presbyla | Jul 16, 2018 | News
PITTSBURGH, July 16, 2018 (GLOBE NEWSWIRE) — Krystal Biotech Inc., (“Krystal”) (NASDAQ:KRYS), a gene therapy company developing topical and intradermal “off-the-shelf” treatments for rare dermatological diseases, today announces a presentation on the Company’s...
by Mike Presbyla | May 24, 2018 | News
PITTSBURGH, May 24, 2018 (GLOBE NEWSWIRE) — Krystal Biotech Inc., (“Krystal”) (NASDAQ:KRYS), a gene therapy company developing topical and intradermal “off-the-shelf” treatments for rare dermatological diseases, today announces that the U.S. Food and...
United States
Germany
France
